Eirini Thanopoulou

814 total citations · 1 hit paper
26 papers, 401 citations indexed

About

Eirini Thanopoulou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Eirini Thanopoulou has authored 26 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Eirini Thanopoulou's work include Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (8 papers). Eirini Thanopoulou is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (8 papers). Eirini Thanopoulou collaborates with scholars based in United Kingdom, Germany and South Korea. Eirini Thanopoulou's co-authors include Ian Judson, Stephen Johnston, Claudia Omarini, Komel Khabra, Khin Thway, Charles Swanton, Mariam Jamal‐Hanjani, Dejan Juric, Aleksandar Aleksić and Peter Schmid and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Eirini Thanopoulou

23 papers receiving 395 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer

2025 16 citations Komal Jhaveri, Seock‐Ah Im et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eirini Thanopoulou United Kingdom	12	158	148	121	113	56	26	401
Christel De Pooter Belgium	8	96 0.6×	218 1.5×	360 3.0×	168 1.5×	43 0.8×	11	530
Cristina Bilbao Spain	12	63 0.4×	101 0.7×	203 1.7×	94 0.8×	65 1.2×	31	456
Yulin L. Liu United States	9	220 1.4×	263 1.8×	254 2.1×	137 1.2×	17 0.3×	11	600
Pritesh Trivedi United Kingdom	11	83 0.5×	189 1.3×	139 1.1×	88 0.8×	15 0.3×	20	402
Kimiyo Tabata Japan	7	158 1.0×	365 2.5×	97 0.8×	82 0.7×	42 0.8×	12	665
Lauren Moran United States	5	178 1.1×	169 1.1×	299 2.5×	42 0.4×	12 0.2×	5	424
A. Valent France	10	125 0.8×	155 1.0×	101 0.8×	89 0.8×	8 0.1×	18	318
YounJeong Choi United States	11	106 0.7×	206 1.4×	135 1.1×	51 0.5×	11 0.2×	17	369
E Sivridis Greece	9	68 0.4×	152 1.0×	189 1.6×	103 0.9×	69 1.2×	19	387
Émeline Colomba France	12	245 1.6×	307 2.1×	216 1.8×	98 0.9×	29 0.5×	71	526

Countries citing papers authored by Eirini Thanopoulou

Since Specialization

Citations

This map shows the geographic impact of Eirini Thanopoulou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eirini Thanopoulou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eirini Thanopoulou more than expected).

Fields of papers citing papers by Eirini Thanopoulou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eirini Thanopoulou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eirini Thanopoulou. The network helps show where Eirini Thanopoulou may publish in the future.

Co-authorship network of co-authors of Eirini Thanopoulou

This figure shows the co-authorship network connecting the top 25 collaborators of Eirini Thanopoulou. A scholar is included among the top collaborators of Eirini Thanopoulou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eirini Thanopoulou. Eirini Thanopoulou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lambert, Peter, Eirini Thanopoulou, & Preet K. Dhillon. (2025). Abstract P4-07-27: Real-world observational study of patients with endocrine-resistant, hormone receptor+, HER2- metastatic breast cancer in the first-line setting: Patient characteristics, PIK3CA mutation prevalence, treatments, and clinical outcomes. Clinical Cancer Research. 31(12_Supplement). P4–7.

Turner, Nicholas C., Seock‐Ah Im, Cristina Saura, et al.. (2025). INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).. Journal of Clinical Oncology. 43(16_suppl). 1003–1003. 2 indexed citations

Jhaveri, Komal, Seock‐Ah Im, Cristina Saura, et al.. (2025). Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine. 393(2). 151–161. 16 indexed citations breakdown →

Juric, Dejan, Kevin Kalinsky, Nicholas C. Turner, et al.. (2024). First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.. Journal of Clinical Oncology. 42(16_suppl). 1003–1003. 23 indexed citations

Jhaveri, Komal, Seock‐Ah Im, Cristina Saura, et al.. (2024). Abstract GS03-13: Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. Cancer Research. 84(9_Supplement). GS03–13. 16 indexed citations

Juric, Dejan, Kevin Kalinsky, Seock‐Ah Im, et al.. (2023). INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).. Journal of Clinical Oncology. 41(16_suppl). TPS1123–TPS1123. 11 indexed citations

Turner, Nicholas C., Komal Jhaveri, Kevin Kalinsky, et al.. (2021). Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC). Cancer Research. 81(4_Supplement). OT–36. 1 indexed citations

Turner, Nicholas C., Komal Jhaveri, Kevin Kalinsky, et al.. (2020). 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC). Annals of Oncology. 31. S391–S392. 6 indexed citations

Thanopoulou, Eirini, Morena Caira, Andrew Wardley, et al.. (2020). Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. Cancers. 12(11). 3317–3317. 20 indexed citations

10.

Jamal‐Hanjani, Mariam, Roger A’Hern, Nicolai J. Birkbak, et al.. (2015). Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. Annals of Oncology. 26(7). 1340–1346. 63 indexed citations

11.

Thanopoulou, Eirini, Aleksandar Aleksić, Khin Thway, Komel Khabra, & Ian Judson. (2015). Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital. PubMed. 5(1). 8–8. 24 indexed citations

12.

Thanopoulou, Eirini, Alicia Okines, Kiruthikah Thillai, et al.. (2014). Febrile Neutropaenia and Chemotherapy Discontinuation in Women Aged 70 Years or Older Receiving Adjuvant Chemotherapy for Early Breast Cancer. Clinical Oncology. 26(11). 692–696. 10 indexed citations

13.

Omarini, Claudia, Eirini Thanopoulou, & Stephen Johnston. (2014). Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Research and Treatment. 146(2). 245–258. 44 indexed citations

14.

Thanopoulou, Eirini, Khin Thway, Komel Khabra, & Ian Judson. (2014). Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. PubMed. 4(1). 5–5. 24 indexed citations

15.

Jamal‐Hanjani, Mariam, Eirini Thanopoulou, Karl S. Peggs, Sergio A. Quezada, & Charles Swanton. (2013). Tumour heterogeneity and immune-modulation. Current Opinion in Pharmacology. 13(4). 497–503. 25 indexed citations

16.

Thanopoulou, Eirini, Ioannis S. Pateras, Alexandros Papalambros, et al.. (2012). The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. Tumor Biology. 33(5). 1429–1436. 20 indexed citations

17.

Thanopoulou, Eirini & Ian Judson. (2012). Hormonal therapy in gynecological sarcomas. Expert Review of Anticancer Therapy. 12(7). 885–894. 23 indexed citations

18.

Thanopoulou, Eirini & Ian Judson. (2011). The safety profile of imatinib in CML and GIST: long-term considerations. Archives of Toxicology. 86(1). 1–12. 51 indexed citations

19.

Terzoudi, Aikaterini, Konstantinos Kamposioras, Antonis Valachis, et al.. (2010). Evaluating the strength of potential misplaced priorities in opportunistic cancer screening practice in Greece.. PubMed. 15(1). 164–73. 1 indexed citations

20.

Tsiambas, Evangelos, et al.. (2005). Morphometric study of immunohistochemical expression of topoisomerase IIa and p16 correlating with molecular detection of chromosome 17 and 9 instability, in pancreatic adenocarcinoma, using Tissue Microarrays application. Journal of Clinical Oncology. 23(16_suppl). 4100–4100. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact